Danaher Corporation $DHR Shares Acquired by Eastern Bank

Eastern Bank increased its holdings in Danaher Corporation (NYSE:DHR) by 2.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 190,640 shares of the conglomerate’s stock after acquiring an additional 4,107 shares during the quarter. Eastern Bank’s holdings in Danaher were worth $37,796,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Modern Wealth Management LLC boosted its stake in shares of Danaher by 42.7% during the first quarter. Modern Wealth Management LLC now owns 1,521 shares of the conglomerate’s stock worth $312,000 after buying an additional 455 shares during the period. Parallel Advisors LLC raised its stake in Danaher by 9.9% during the 2nd quarter. Parallel Advisors LLC now owns 19,141 shares of the conglomerate’s stock valued at $3,781,000 after acquiring an additional 1,732 shares during the last quarter. Apella Capital LLC lifted its position in Danaher by 4.1% during the 2nd quarter. Apella Capital LLC now owns 2,261 shares of the conglomerate’s stock worth $451,000 after acquiring an additional 89 shares during the period. MassMutual Private Wealth & Trust FSB grew its stake in shares of Danaher by 7.5% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 117,426 shares of the conglomerate’s stock valued at $23,196,000 after purchasing an additional 8,218 shares during the last quarter. Finally, Sandy Cove Advisors LLC increased its holdings in shares of Danaher by 1.8% in the second quarter. Sandy Cove Advisors LLC now owns 5,631 shares of the conglomerate’s stock valued at $1,112,000 after purchasing an additional 97 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.5%

DHR stock opened at $235.40 on Wednesday. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average price is $226.70 and its 200 day moving average price is $211.20. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23. The company has a market cap of $166.27 billion, a P/E ratio of 48.54, a P/E/G ratio of 4.25 and a beta of 0.89.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.71 EPS. On average, research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, December 26th. Danaher’s payout ratio is presently 26.39%.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 3,298 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the sale, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This represents a 13.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the transaction, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 30,248 shares of company stock valued at $6,609,663. Insiders own 11.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Jefferies Financial Group increased their price target on Danaher from $245.00 to $255.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Redburn Partners set a $220.00 price target on shares of Danaher in a research note on Wednesday, October 8th. Weiss Ratings restated a “hold (c)” rating on shares of Danaher in a research report on Monday, December 29th. Finally, Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Twenty-one analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $249.92.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Management raised FY‑2025 EPS guidance to $7.80 (vs. consensus ~$7.71), signalling confidence in near‑term earnings execution — a direct driver of upside expectations for the stock.
• Positive Sentiment: Danaher said Q4 revenue is tracking at the high end of guidance on strength in bioprocessing, indicating better-than-expected top-line momentum in a core growth area. Danaher Forecasts 4Q Revenue at High-End of Guidance on Bioprocessing Strength — Update
• Positive Sentiment: Equity research support: William Blair reiterated a Buy rating, arguing Danaher’s broad-based outperformance and growth justify a premium multiple — helps underpin investor confidence. Danaher: Buy Rating Reiterated on Broad-Based Outperformance and Premium-Justified Growth Outlook
• Positive Sentiment: Fund flows/manager positioning: Mar Vista flagged Danaher as a top contributor in Q4 for its U.S. Quality strategy, signalling institutional demand from quality-oriented funds. Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors
• Neutral Sentiment: Management commentary: Danaher presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for detail on strategy and outlook but largely reiterative; may not move the stock much unless new incremental news emerged. Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: CEO commentary scheduled/posted around Q4 results (PR release) — offers management color but is expected given the earnings cadence. Danaher CEO to Comment on Financial Performance
• Positive Sentiment: Zacks issued a positive estimate lift for Danaher earnings, adding analyst backing to the outlook. Zacks Research Issues Positive Estimate for Danaher Earnings
• Negative Sentiment: Insider selling flagged in recent reporting — raises near-term caution for some investors and can weigh on sentiment, particularly after a strong run-up. Possible Bearish Signals With Danaher Insiders Disposing Stock
• Negative Sentiment: High valuation (current PE ~48x) and recent gains increase the risk of profit-taking and short-term pullbacks despite positive fundamentals — likely a contributor to today’s weakness.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.